Using glycosaminoglycan/chemokine interactions for the long-term delivery of 5P12-RANTES in HIV prevention

Molecular Pharmaceutics

Volumn 10, Issue 10, 2013, Pages 3564-3573

  Wang, Nick X ^a   Sieg, Scott F ^b   Lederman, Michael M ^b   Offord, Robin E ^c   Hartley, Oliver ^d   Von Recum, Horst A ^a  

^a Case Western Reserve University   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Mintaka Foundation   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

CCL5; CCR5; Chemokine; Drug delivery; Glycosaminoglycans; Heparin; HIV; Microbicide; Prevention

Indexed keywords

5P12 RANTES; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; GLYCOSAMINOGLYCAN; POLYMER; RANTES; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHEMICAL COMPOSITION; CHEMICAL INTERACTION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG RECEPTOR BINDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEL; IN VITRO STUDY; PHARMACEUTICAL ENGINEERING; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; SUSTAINED DRUG RELEASE;

CHEMOKINES; CHEMOKINES, CC; DRUG CARRIERS; GLYCOSAMINOGLYCANS; HIV INFECTIONS; HUMANS; POLYMERS; SURFACE PLASMON RESONANCE;

EID: 84888321311     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3007242     Document Type: Article

References (39)

1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010; Joint United Nations Programme on HIV/AIDS: Geneva, 2010.
2. Feldblum, P. J.; Fortney, J. A. Condoms, spermicides, and the transmission of human immunodeficiency virus: a review of the literature. Am. J. Public Health 1988, 78 (1), 52-4.
3. Auvert, B.; Taljaard, D.; Lagarde, E.; Sobngwi-Tambekou, J.; Sitta, R.; Puren, A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005, 2 (11), e298.
4. Banerjee, J.; Klausner, J. D.; Halperin, D. T.; Wamai, R.; Schoen, E. J.; Moses, S.; Morris, B. J.; Bailis, S. A.; Venter, F.; Martinson, N.; Coates, T. J.; Gray, G.; Bowa, K. Circumcision denialism unfounded and unscientific. Am. J. Prev. Med. 2011, 40 (3), e11-2-4.
5. Nel, A. M.; Coplan, P.; van de Wijgert, J. H.; Kapiga, S. H.; von Mollendorf, C.; Geubbels, E.; Vyankandondera, J.; Rees, H. V.; Masenga, G.; Kiwelu, I.; Moyes, J.; Smythe, S. C. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 2009, 23 (12), 1531-8.
6. Nel, A. M.; Smythe, S. C.; Habibi, S.; Kaptur, P. E.; Romano, J. W. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel. J. Acquir. Immune Defic. Syndr. 2010, 55 (2), 161-9.
7. Selhorst, P.; Vazquez, A. C.; Terrazas-Aranda, K.; Michiels, J.; Vereecken, K.; Heyndrickx, L.; Weber, J.; Quinones-Mateu, M. E.; Arien, K. K.; Vanham, G. Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides. Antimicrob. Agents Chemother. 2011, 55 (4), 1403-13.
8. Nuttall, J.; Kashuba, A.; Wang, R.; White, N.; Allen, P.; Roberts, J.; Romano, J. The Pharmacokinetics of Tenofovir Following Intravaginal and Intrarectal Administration of Tenofovir Gel to Rhesus Macaques. Antimicrob. Agents Chemother. 2012, 56 (1), 103-9.
9. Abdool Karim, Q.; Abdool Karim, S. S.; Frohlich, J. A.; Grobler, A. C.; Baxter, C.; Mansoor, L. E.; Kharsany, A. B.; Sibeko, S.; Mlisana, K. P.; Omar, Z.; Gengiah, T. N.; Maarschalk, S.; Arulappan, N.; Mlotshwa, M.; Morris, L.; Taylor, D. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329 (5996), 1168-74.
10. McGowan, I.; Gomez, K.; Bruder, K.; Febo, I.; Chen, B. A.; Richardson, B. A.; Husnik, M.; Livant, E.; Price, C.; Jacobson, C. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS 2011, 25 (8), 1057-64.
11. Arien, K. K.; Vanham, G. First real success for anti-HIV gel: a new start for HIV microbicides? Fut. Microbiol. 2010, 5 (11), 1621-3.
12. Beyers, N.; Cotton, M. F.; Donald, P. R.; Gie, R. P.; Henning, P. A.; Hesseling, P. B.; Kirsten, G. F.; Kling, S.; Nel, E. D.; Pieper, C. H.; Ravenscroft, A.; Schaaf, H. S.; Schoeman, J. F.; Smith, J.; van Buuren, A. J.; van der Merwe, P. L.; van Schalkwyk, H. J.; Wessels, G. The mother-to-child HIV transmission debate. S. Afr. Med. J. 1999, 89 (2), 104-106.
13. Ammaranond, P.; Sanguansittianan, S. Mechanism of HIV antiretroviral drugs progress toward drug resistance. Fundam. Clin. Pharmacol. 2011, 26 (1), 146-61.
14. Kuritzkes, D. R. Drug Resistance in HIV-1. Curr. Opin. Virol. 2011, 1 (6), 582-589.
15. Pirrone, V.; Thakkar, N.; Jacobson, J. M.; Wigdahl, B.; Krebs, F. C. Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob. Agents Chemother. 2011, 55 (5), 1831-42.
16. Spaulding, A.; Rutherford, G. W.; Siegfried, N. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naive individuals. Cochrane Database Syst. Rev. 2010, 6 (10), CD008740.
17. Garg, A. B.; Nuttall, J.; Romano, J. The future of HIV microbicides: challenges and opportunities. Antivir. Chem. Chemother. 2009, 19 (4), 143-50.
18. Vangelista, L.; Secchi, M.; Lusso, P. Rational design of novel HIV-1 entry inhibitors by RANTES engineering. Vaccine 2008, 26 (24), 3008-15.
19. Lusso, P.; Vangelista, L.; Cimbro, R.; Secchi, M.; Sironi, F.; Longhi, R.; Faiella, M.; Maglio, O.; Pavone, V. Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity. FASEB J. 2011, 25 (4), 1230-43.
20. Hartley, O.; Gaertner, H.; Wilken, J.; Thompson, D.; Fish, R.; Ramos, A.; Pastore, C.; Dufour, B.; Cerini, F.; Melotti, A.; Heveker, N.; Picard, L.; Alizon, M.; Mosier, D.; Kent, S.; Offord, R. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2004, 101 (47), 16460-5.
21. Gaertner, H.; Cerini, F.; Escola, J. M.; Kuenzi, G.; Melotti, A.; Offord, R.; Rossitto-Borlat, I.; Nedellec, R.; Salkowitz, J.; Gorochov, G.; Mosier, D.; Hartley, O. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (46), 17706-11.
22. Nedellec, R.; Coetzer, M.; Lederman, M. M.; Offord, R. E.; Hartley, O.; Mosier, D. E. Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use. PLoS One 2009, 6 (7), e22020.
23. Veazey, R. S.; Ling, B.; Green, L. C.; Ribka, E. P.; Lifson, J. D.; Piatak, M., Jr.; Lederman, M. M.; Mosier, D.; Offord, R.; Hartley, O. Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. J. Infect Dis. 2009, 199 (10), 1525-7.
24. Ham, A. S.; Cost, M. R.; Sassi, A. B.; Dezzutti, C. S.; Rohan, L. C. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm. Res. 2009, 26 (3), 502-11.
25. Wang, N. X.; von Recum, H. A. Affinity-based drug delivery. Macromol. Biosci. 2011, 11 (3), 321-32.
26. Maxwell, D. J.; Hicks, B. C.; Parsons, S.; Sakiyama-Elbert, S. E. Development of rationally designed affinity-based drug delivery systems. Acta Biomater. 2005, 1 (1), 101-13.
27. von Recum, H.; Kikuchi, A.; Yamato, M.; Sakurai, Y.; Okano, T.; Kim, S. W. Growth factor and matrix molecules preserve cell function on thermally responsive culture surfaces. Tissue Eng. 1999, 5 (3), 251-65.
28. Rek, A.; Brandner, B.; Geretti, E.; Kungl, A. J. A biophysical insight into the RANTES-glycosaminoglycan interaction. Biochim. Biophys. Acta 2009, 1794 (4), 577-82.
29. Martin, L.; Blanpain, C.; Garnier, P.; Wittamer, V.; Parmentier, M.; Vita, C. Structural and functional analysis of the RANTESglycosaminoglycans interactions. Biochemistry 2001, 40 (21), 6303-18.
30. Brandner, B.; Rek, A.; Diedrichs-Mohring, M.; Wildner, G.; Kungl, A. J. Engineering the glycosaminoglycan-binding affinity, kinetics and oligomerization behavior of RANTES: a tool for generating chemokine-based glycosaminoglycan antagonists. Protein Eng. Des. Sel. 2009, 22 (6), 367-73.
31. Proudfoot, A. E.; Fritchley, S.; Borlat, F.; Shaw, J. P.; Vilbois, F.; Zwahlen, C.; Trkola, A.; Marchant, D.; Clapham, P. R.; Wells, T. N. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J. Biol. Chem. 2001, 276 (14), 10620-6.
32. Duo, J.; Stenken, J. A. Heparin-immobilized microspheres for the capture of cytokines. Anal. Bioanal. Chem. 2011, 399 (2), 773-82.
33. Duo, J.; Stenken, J. A. In vitro and in vivo affinity microdialysis sampling of cytokines using heparin-immobilized microspheres. Anal. Bioanal. Chem. 2011, 399 (2), 783-93.
34. von Recum, H. A.; Pokorski, J. K. Peptide and Protein-based Inhibitors of HIV-1 Co-receptors. Exp. Biol. Med. 2013, 238, 442-9.
35. Aka-Any-Grah, A.; Bouchemal, K.; Koffi, A.; Agnely, F.; Zhang, M.; Djabourov, M.; Ponchel, G. Formulation of mucoadhesive vaginal hydrogels insensitive to dilution with vaginal fluids. Eur. J. Pharm. Biopharm. 2010, 76 (2), 296-303.
36. Hu, Q.; Huang, X.; Shattock, R. J. C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to smallmolecule CCR5 inhibitors. J. Gen. Virol. 2010, 91 (Pt 12), 2965-73.
37. Wu, L.; LaRosa, G.; Kassam, N.; Gordon, C. J.; Heath, H.; Ruffing, N.; Chen, H.; Humblias, J.; Samson, M.; Parmentier, M.; Moore, J. P.; Mackay, C. R. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 1997, 186 (8), 1373-81.
38. Sarkar, N. N. The combined contraceptive vaginal device (NuvaRing): a comprehensive review. Eur. J. Contracept Reprod. Health Care 2005, 10 (2), 73-8.
39. Cerini, F.; Landay, A.; Gichinga, C.; Lederman, M. M.; Flyckt, R.; Starks, D.; Offord, R. E.; Le Gal, F.; Hartley, O. Chemokine analogues show suitable stability for development as microbicides. J. Acquir. Immune Defic. Syndr. 2008, 49 (5), 472-6.